News
Merck HQ

Merck drug for rare tumour hits phase 3 target

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 tr

Debates & Insights

News

Press Releases

Newsletters and Deep Dive
digital magazine

Views & Analysis

Webinars

Podcasts

Video

White Papers

Event

Partner Content